DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells

Exp Oncol. 2010 Dec;32(4):258-62.

Abstract

Aim: To perform the comparative study of the effects of DNA-dependent protein kinase (DNA-PK) inhibitors vanillin and NU7026, ataxia telangiectasia mutated kinase (ATM)/ ATM and Rad3 related (ATR) kinase inhibitor caffeine and multidrug resistance (MDR) protein modulator cyclosporine A (CsA) on fludarabine resistant and sensitive lymphocytes from chronic lymphocytic leukemia (CLL) patients.

Methods: Cells sensitivity in vitro was determined with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT). DNA-PKs and ATM expression in CLL cells was evaluated using Western blotting. Multidrug tansporter protein expression and function was assessed by flow cytometry. Pro- or anti-apoptotic genes (BAX, LICE BCL-2, BCL-XS FLICE, FAS, TRAIL) expression on mRNA level was evaluated.

Results: Caffeine, vanillin, NU7026 and CsA increased fludarabine cytotoxicity against fludarabine-resistant CLL cells samples in comparison with sensitive cell samples. However, fludarabine-sensitive CLL samples were sensitized with inhibitors to a greater extent compared with resistant CLL samples. ATM expression increased in fludarabine-resistant CLL samples, but no apparent correlation between DNA-PKs level and fludarabine sensitivity in vitro or sensitization effect of DNA-PK inhibitors were observed. Fludarabine-resistant CLL lymphocytes showed tendency for depressed MDR efflux and decreased level of mRNA of pro-apoptotic gene BCL-XS.

Conclusion: Absence of any definite conformity between fludarabine-resistant cell susceptibility to combined action of fludarabine and inhibitors, and molecular pathways that might be involved in this process does not exclude drugs synergy in fludarabine-resistant cells that could be used for overcoming resistance to nucleoside analogs in CLL.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B / antagonists & inhibitors*
  • Antineoplastic Agents / pharmacology
  • Ataxia Telangiectasia Mutated Proteins
  • Benzaldehydes / pharmacology
  • Blotting, Western
  • Caffeine / pharmacology
  • Cell Cycle Proteins / antagonists & inhibitors*
  • Cell Line, Tumor
  • Chromones / pharmacology
  • Cyclosporine / pharmacology
  • DNA-Activated Protein Kinase / antagonists & inhibitors*
  • DNA-Binding Proteins / antagonists & inhibitors*
  • Drug Resistance, Neoplasm / drug effects*
  • Flow Cytometry
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
  • Morpholines / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Tumor Suppressor Proteins / antagonists & inhibitors*
  • Vidarabine / analogs & derivatives
  • Vidarabine / pharmacology

Substances

  • 2-(morpholin-4-yl)benzo(h)chromen-4-one
  • ATP Binding Cassette Transporter, Subfamily B
  • Antineoplastic Agents
  • Benzaldehydes
  • Cell Cycle Proteins
  • Chromones
  • DNA-Binding Proteins
  • Morpholines
  • Protein Kinase Inhibitors
  • Tumor Suppressor Proteins
  • Caffeine
  • Cyclosporine
  • vanillin
  • ATM protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • DNA-Activated Protein Kinase
  • Protein Serine-Threonine Kinases
  • Vidarabine
  • fludarabine